3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
4
Phase 2/3
2
Phase 1/2
2
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
43
Leukemia
7
Myelodysplastic Syndromes
4
Leukemia, Myelomonocytic, Chronic
4
Recurrence
2
Pathologic Complete Response
2
Neoplasms
2
MDS
1
Lymphoma, T-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Myeloid
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Higher-risk Myelodysplastic Syndrome
1
Hematologic Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cytarabine
9
Daunorubicin
7
Etoposide
6
Methotrexate
5
Idarubicin
5
Thioguanine
4
Mitoxantrone
4
Cyclophosphamide
4
Hydrocortisone
3
Granulocyte Colony-Stimulating Factor
3
Filgrastim
3
Asparaginase
3
Tacrolimus
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
ON 01910
2
Mycophenolic Acid
2
Dexamethasone
2
Busulfan
2
zosuquidar trihydrochloride
1
valspodar
1
tipifarnib
1
sargramostim
1
palmitoyl-L-asparaginase
1
merphos
1
lonafarnib
1
hydrocortisone hemisuccinate
1
fludarabine phosphate
1
fludarabine
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Anemia, Refractory, with Excess of Blasts
×
Azacitidine
×
Clear all
NCT04173533
2024-05-14
AMADEUS
University of Birmingham
Phase 3
Unknown
326 enrolled